المؤلفون: Chu Q; Cross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada., Sripada K; Hoffmann-La Roche, Mississauga, ON L5N 5M8, Canada., Vaselenak S; Hoffmann-La Roche, Mississauga, ON L5N 5M8, Canada., Jovanoski N; F. Hoffmann-La Roche Ltd., 4052 Basel, Switzerland., Arnold M; F. Hoffmann-La Roche Ltd., 4052 Basel, Switzerland.

المصدر: Current oncology (Toronto, Ont.) [Curr Oncol] 2024 Jun 07; Vol. 31 (6), pp. 3301-3310. Date of Electronic Publication: 2024 Jun 07.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 9502503 Publication Model: Electronic Cited Medium: Internet ISSN: 1718-7729 (Electronic) Linking ISSN: 11980052 NLM ISO Abbreviation: Curr Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/economics , Carcinoma, Non-Small-Cell Lung*/pathology , Lung Neoplasms*/drug therapy , Lung Neoplasms*/economics , Lung Neoplasms*/pathology , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/economics, Humans ; Canada ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Staging ; Chemotherapy, Adjuvant/methods ; Chemotherapy, Adjuvant/economics ; Cost Savings ; Female ; Male ; Aged ; Middle Aged

المؤلفون: O'Sullivan DE; Department of Oncology, University of Calgary, Calgary, AB T2N 1N4, Canada.; Department of Community Health Sciences, University of Calgary, Calgary, AB T2N 1N4, Canada.; Oncology Outcomes Initiative, University of Calgary, Calgary, AB T2N 1N4, Canada., Boyne DJ; Department of Oncology, University of Calgary, Calgary, AB T2N 1N4, Canada.; Department of Community Health Sciences, University of Calgary, Calgary, AB T2N 1N4, Canada.; Oncology Outcomes Initiative, University of Calgary, Calgary, AB T2N 1N4, Canada., Ford-Sahibzada C; Department of Community Health Sciences, University of Calgary, Calgary, AB T2N 1N4, Canada.; Oncology Outcomes Initiative, University of Calgary, Calgary, AB T2N 1N4, Canada., Inskip JA; Hoffmann-La Roche Limited, Mississauga, ON L5N 5M8, Canada., Smith CJ; Hoffmann-La Roche Limited, Mississauga, ON L5N 5M8, Canada., Sripada K; Hoffmann-La Roche Limited, Mississauga, ON L5N 5M8, Canada., Brenner DR; Department of Oncology, University of Calgary, Calgary, AB T2N 1N4, Canada.; Department of Community Health Sciences, University of Calgary, Calgary, AB T2N 1N4, Canada.; Oncology Outcomes Initiative, University of Calgary, Calgary, AB T2N 1N4, Canada., Cheung WY; Department of Oncology, University of Calgary, Calgary, AB T2N 1N4, Canada.; Department of Community Health Sciences, University of Calgary, Calgary, AB T2N 1N4, Canada.; Oncology Outcomes Initiative, University of Calgary, Calgary, AB T2N 1N4, Canada.

المصدر: Current oncology (Toronto, Ont.) [Curr Oncol] 2024 Jan 12; Vol. 31 (1), pp. 447-461. Date of Electronic Publication: 2024 Jan 12.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 9502503 Publication Model: Electronic Cited Medium: Internet ISSN: 1718-7729 (Electronic) Linking ISSN: 11980052 NLM ISO Abbreviation: Curr Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung*/drug therapy , Lung Neoplasms*/drug therapy , Small Cell Lung Carcinoma*, Humans ; Cohort Studies ; Retrospective Studies ; Alberta ; Delivery of Health Care